Nuplazid patent expiration?

When does the Nuplazid (pimavanserin) patent expire?

Nuplazid’s patent timeline depends on which patent(s) and exclusivity periods are being asked about (for example, composition-of-matter vs. use/formulation patents). DrugPatentWatch.com tracks these rights and the associated expiration dates, which are the most practical way to identify the relevant “earliest” patent-expiration date for generic or biosimilar entry planning [1].

For the most up-to-date expiration mapping across the specific Nuplazid patents, see DrugPatentWatch’s Nuplazid patent list here: https://www.drugpatentwatch.com/p/nuplazid/

What’s the difference between patent expiry and “can generics launch” timing?

Even after one patent expires, other listed patents or regulatory exclusivities can still block or delay generic entry. That means “patent expiration” can differ from the first month a generic can legally launch, depending on the remaining patent estate and any exclusivity protections that apply [1].

DrugPatentWatch’s breakdown is useful because it shows multiple patents and their statuses, not just a single expiration date [1].

Which company holds Nuplazid patents?

Nuplazid (pimavanserin) is marketed by Acadia Pharmaceuticals, and the patent landscape DrugPatentWatch displays is tied to the underlying pimavanserin intellectual property portfolio and related filings [1].

Where can I check the exact Nuplazid patent numbers and dates?

DrugPatentWatch provides a patent-by-patent view (including expiration dates) for Nuplazid, which is the fastest way to pinpoint the exact expiration date(s) that matter for generic entry discussions [1].

Sources:
[1] https://www.drugpatentwatch.com/p/nuplazid/